DERM Journey Medical (DERM) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001867066
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
43
13F, latest reported quarter
Journey Medical insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Journey Medical Corp in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 11 earlier Form 4 trades (code P or S) here by this insider (2 buys, 9 sales), the last on Mar 11, 2025.
- +97.2% median (+97.2% mean) 90-day return after 2 previous buys.
- The trade is 0.2% of the 2,348,313 shares held after it.
- 2 other insiders sold within 30 days.
- 43 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Maraoui Claude sold about $33.1K of DERM on May 2, 2025; 2 other insiders sold within 30 days and 43 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Feb 21, 2025.
- The trade is 1.2% of the 203,557 shares held after it.
- 2 other insiders sold within 30 days.
- 43 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CFO Benesch Joseph sold about $16.5K of DERM on May 2, 2025; 2 other insiders sold within 30 days and 43 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 0.6% of the 504,817 shares held after it.
- 2 other insiders sold within 30 days.
- 43 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: COO Alloush Ramsey sold about $19.5K of DERM on May 2, 2025; 2 other insiders sold within 30 days and 43 funds added in the latest 13F quarter.Context
- 10 earlier Form 4 trades (code P or S) here by this insider (2 buys, 8 sales), the last on Mar 7, 2025.
- +97.2% median (+97.2% mean) 90-day return after 2 previous buys.
- The trade is 2.5% of the 2,003,147 shares held after it.
- 1 other insider sold within 30 days.
- 43 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Maraoui Claude sold about $246.8K of DERM on Mar 11, 2025, the largest insider sale at the company on our record; 1 other insider sold within 30 days and 43 funds added in the latest 13F quarter.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (2 buys, 7 sales), the last on Mar 6, 2025.
- +97.2% median (+97.2% mean) 90-day return after 2 previous buys.
- The trade is 0.7% of the 2,052,418 shares held after it.
- 1 other insider sold within 30 days.
- 43 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Maraoui Claude sold about $74.7K of DERM on Mar 7, 2025; 1 other insider sold within 30 days and 43 funds added in the latest 13F quarter.31 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
43 funds bought in last quarter
below 56% of Pharma & Biotech
Revenue
+11.1% year over year
more than 60% of Pharma & Biotech
Margin
-18.7% net margin
more than 59% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
19.6% of the float short (float per yahoo 2026-10-26) · 13.9 days to cover · settled 2026-09-30
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch DERM
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-33.1%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns DERM: institutional holders (13F)
13F holdings, latest reported quarter
2,858,930 sh
$20.2M
1,610,000 sh
$11.4M
675,185 sh
$4.8M
$3.8M
528,584 sh
$3.7M
Congress trades in DERM
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
DERM planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
DERM mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Wasatch Micro Cap Value Fund
$5.6M position · as of 2026-06-30
1.4%
Wasatch Micro Cap Fund
$9.2M position · as of 2026-06-30
1.4%
Invesco NASDAQ Future Gen 200 ETF
$59.3K position · as of 2026-05-31
0.3%
iShares Micro-Cap ETF
$360.6K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$23.9K position · as of 2026-06-30
0.0%
VANGUARD RUSSELL 2000 GROWTH INDEX FUND
$120.7K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 0 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
2
Phase 1
0 active
1
Phase 2
0 active
2
Phase 3
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 43 funds added last quarter. Each figure is a federal filing, dated the day it went public.
DERM financials
Revenue growth
+11.1%
XBRL, annual
Net margin
-18.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$68.2M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM DERM
| FY Dec 2025 | $61.9M |
| FY Dec 2024 | $56.1M |
| FY Dec 2023 | $79.2M |
| FY Dec 2022 | $73.7M |
| FY Dec 2021 | $63.1M |
| Jun 2026 | $18.5M |
| Mar 2026 | $16.0M |
| Dec 2025 | $16.1M |
| Sep 2025 | $17.6M |
| Jun 2025 | $15.0M |
| Mar 2025 | $13.1M |
| Dec 2024 | $13.6M |
| Sep 2024 | $14.6M |
At each fiscal year end
Single quarter
Net margin, TTM
-9.0%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM DERM
| FY Dec 2025 | -18.5% |
| FY Dec 2024 | -26.1% |
| FY Dec 2023 | -4.9% |
| FY Dec 2022 | -40.2% |
| FY Dec 2021 | -69.7% |
| Jun 2026 | -1.7% |
| Mar 2026 | -14.0% |
| Dec 2025 | -7.8% |
| Sep 2025 | -13.1% |
| Jun 2025 | -25.3% |
| Mar 2025 | -31.0% |
| Dec 2024 | +11.2% |
| Sep 2024 | -16.3% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$12.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM DERM
| FY Dec 2025 | -$17.4M |
| FY Dec 2024 | -$14.1M |
| FY Dec 2023 | $240.0K |
| FY Dec 2022 | -$33.5M |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
0.79x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity DERM
| FY Dec 2025 | 0.97x |
| FY Dec 2024 | 1.74x |
| FY Dec 2023 | 1.21x |
| FY Dec 2022 | 1.17x |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.79x |
| Mar 2026 | 0.82x |
| Dec 2025 | 0.97x |
| Sep 2025 | 0.97x |
| Jun 2025 | 1.30x |
| Mar 2025 | 1.16x |
| Dec 2024 | 1.74x |
| Sep 2024 | 2.72x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.29x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt DERM
| FY Dec 2025 | -0.40x |
| FY Dec 2024 | -0.26x |
| FY Dec 2023 | 0.21x |
| FY Dec 2022 | -0.68x |
| FY Dec 2021 | n/a |
| Jun 2026 | -0.29x |
| Mar 2026 | -0.26x |
| Dec 2025 | -0.40x |
| Sep 2025 | -0.16x |
| Jun 2025 | -0.11x |
| Mar 2025 | -0.28x |
| Dec 2024 | -0.26x |
| Sep 2024 | -0.94x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-23.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity DERM
| FY Dec 2025 | -44.0% |
| FY Dec 2024 | -72.6% |
| FY Dec 2023 | -20.6% |
| FY Dec 2022 | -100.4% |
| FY Dec 2021 | -168.1% |
| Jun 2026 | -23.8% |
| Mar 2026 | -36.6% |
| Dec 2025 | -44.0% |
| Sep 2025 | -47.1% |
| Jun 2025 | -57.2% |
| Mar 2025 | -48.1% |
| Dec 2024 | -72.6% |
| Sep 2024 | -129.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-6.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets DERM
| FY Dec 2025 | -13.1% |
| FY Dec 2024 | -18.7% |
| FY Dec 2023 | -4.2% |
| FY Dec 2022 | -29.3% |
| FY Dec 2021 | -59.0% |
| Jun 2026 | -6.8% |
| Mar 2026 | -10.9% |
| Dec 2025 | -13.1% |
| Sep 2025 | -11.6% |
| Jun 2025 | -11.9% |
| Mar 2025 | -11.0% |
| Dec 2024 | -18.7% |
| Sep 2024 | -28.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital DERM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-6.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed DERM
| FY Dec 2025 | -16.0% |
| FY Dec 2024 | -34.2% |
| FY Dec 2023 | -5.7% |
| FY Dec 2022 | -65.5% |
| FY Dec 2021 | -100.4% |
| Jun 2026 | -6.5% |
| Mar 2026 | -12.9% |
| Dec 2025 | -16.0% |
| Sep 2025 | -14.4% |
| Jun 2025 | -19.1% |
| Mar 2025 | -19.1% |
| Dec 2024 | -34.2% |
| Sep 2024 | -74.9% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing DERM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no share count filed
Enterprise value DERM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
no share count filed
FCF yield DERM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing DERM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $61.9M | $56.1M | $79.2M | $73.7M |
| Operating income | -$8.2M | -$13.7M | -$2.1M | -$27.5M |
| Net income | -$11.4M | -$14.7M | -$3.9M | -$29.6M |
| EPS (diluted) | -0.47 | -0.72 | -0.21 | -1.69 |
| Operating cash flow | -$12.4M | -$9.1M | $5.2M | -$13.5M |
| Cash | $24.1M | $20.3M | $27.4M | $32.0M |
| Long-term debt | $25.3M | $24.9M | $14.6M | $19.8M |
SEC XBRL, fiscal years, as known on 2026-10-28
DERM Stock Sonar score 5/7 axes
Find similar shapesCompareDERM ranks highest on profitability (76th percentile) and growth (60th), and lowest on risk and compliance (42nd), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
